Table 3.
Biomarkers for subarachnoid hemorrhage
Author/year/Ref | Study design | Population | N | Bio-marker | Sample source | Findings |
---|---|---|---|---|---|---|
Molecules of CNS origin | ||||||
Weismann/1997/[31] | Pro | Aneurysmal SAH within 3 days of ictus | 70 | s100β | Serum |
|
Stranjalis/2007/[32] | Pro | Spontaneous SAH within 48 h of ictus | 52 | s100β | Serum |
|
Oertel/2006/[33] | Pro | Aneurysmal SAH | 51 | s100β, NSE | Serum |
|
Coplin/1999/[34] | Pro | Aneurysmal SAH | 27 | CKBB | CSF |
|
Inflammatory markers | ||||||
Pan/2013/[65] | Pro | Aneurysmal SAH | 262 SAH, 150 CTRL | pGSN | Blood |
|
Frijns/2006/[48] | Pro | SAH within 72 h of ictus, exclude perimesencephalic SAH | 106 | vWF | Serum |
|
Mack/2002/[47] | Pro | SAH, excluding those with pro-inflammatory disease process | 80 | sICAM-1 | Serum |
|
Beeftink/2011/[46] | Pro | Aneurysmal SAH | 67 | TNFα, Leukocytes, CRP | Serum |
|
Chou/2011/[38] | Pro | Spontaneous SAH, within 96 h of ictus | 55 | MMP-9 | CSF |
|
Chou/2011/[38] | Pro | Spontaneous SAH, within 96 h of ictus | 55 | Neutrophil, WBC | Blood |
|
Chou/2012/[50] | Pro | Spontaneous SAH, within 96 h of ictus | 52 | TNFα, IL-6 | Serum |
|
Chou/2011/[64] | Pro | Spontaneous SAH, within 96 h of ictus | 42 | pGSN | CSF, Serum |
|
Fassbender/2001/[52] | Pro | Aneurysmal SAH within 48 h of ictus | 35 | IL-1β, IL-6, TNFα | CSF, Serum |
|
Mathiesen/1997/[53] | Pro | SAH patients with EVD | 22 | IL-1Rα, TNFα | CSF |
|
Weir/1989/[43] | Retro | Aneurysmal SAH with vital signs and CBC data (76 % missing data) | 173 | WBC | Blood |
|
Niikawa/1997/[39] | Retro | Fisher grade 3 SAH treated with aneurysm clipping within 24 h of ictus | 103 | WBC | Blood |
|
Other biomarkers | ||||||
Niskakangas/2001/[79] | Case control | Aneurysmal SAH | 108 | ApoE4 | Blood |
|
Juvela/2009/[76] | Case control | SAH within 48 h of ictus | 105 | ε2, ε4–containing genotypes | Blood |
|
Lanterna/2005/[78] | Case control | SAH HH grade 1–3 | 101 | ApoE4 genotype | Blood |
|
Leung/2002/[77] | Case control | Spontaneous SAH | 72 | ApoE4 genotype | Blood |
|
Kay/2003/[81] | Case Control | Spontaneous SAH requiring EVD | 19 | s100β, ApoE | CSF |
|
Lanterna/2005/[78] | Meta-analysis | Consecutive SAH, with 3-month follow-up data | 696 | ApoE4 genotype | Blood |
|
Moussouttas/2012/[88] | Pro | SAH with EVD, HH grade 3–5, endovascular aneurysm treatment | 102 | Epinephrine | CSF |
|
Yarlagadda/2006/[84] | Pro | Spontaneous SAH, >21 years | 300 | BNP, cTI | Serum |
|
Naidech/2005/[82] | Pro | Spontaneous non-traumatic SAH | 253 | cTI | Serum |
|
Ramappa/2008/[83] | Retro | SAH diagnosed by CT scan or CSF, SAH ICD-9 code, with cTI measured | 83 | cTI | Blood |
|
Pro prospective observational, Retro retrospective, CTRL control subjects, CBC complete blood count, HH grade hunt and hess grade, WFNS World Federation of Neurosurgeons Classification, DIND delayed ischemic neurological deficit, DCI delayed cerebral ischemia, mRS modified Rankins score, OR odds ratio